New hope for transplant patients fighting cancer without harsh chemo
NCT ID NCT06040320
Summary
This study is testing whether combining two drugs—polatuzumab vedotin and rituximab—is safe and effective for treating a type of lymphoma that can develop after an organ or stem cell transplant. The goal is to control the cancer while avoiding the severe side effects of traditional chemotherapy. Researchers will enroll about 12 adults with this specific post-transplant condition to evaluate the treatment's safety and how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.